• Mutation; HGNC; HGNC:11998; TP53; None_reported; -; Zygosity=- (PubMed=15153938).
  

PubMed=1500230; DOI=10.1002/ijc.2910520115
Mobus V.J., Gerharz C.-D., Press U., Moll R., Beck T., Mellin W., Pollow K., Knapstein P.-G., Kreienberg R.
Morphological, immunohistochemical and biochemical characterization of 6 newly established human ovarian carcinoma cell lines.
Int. J. Cancer 52:76-84(1992)

PubMed=21559638; DOI=10.3892/ijo.5.4.753
Will C., Wilhelm O.G., Hohl S., Mobus V.J., Weidle U.H., Kreienberg R., Janicke F., Schmitt M., Graeff H.
Expression of urokinase-type plasminogen-activator (uPA) and its receptor (uPAR) in human ovarian-cancer cells and in-vitro invasion capacity.
Int. J. Oncol. 5:753-761(1994)

PubMed=11242531; DOI=10.1089/10430340150504019
Bruning A., Kohler T., Quist S.R., Wang-Gohrke S., Mobus V.J., Kreienberg R., Runnebaum I.B.
Adenoviral transduction efficiency of ovarian cancer cells can be limited by loss of integrin beta3 subunit expression and increased by reconstitution of integrin alphaVbeta3.
Hum. Gene Ther. 12:391-399(2001)

PubMed=15153938; DOI=10.1038/sj.cgt.7700727
Quist S.R., Wang-Gohrke S., Kohler T., Kreienberg R., Runnebaum I.B.
Cooperative effect of adenoviral p53 gene therapy and standard chemotherapy in ovarian cancer cells independent of the endogenous p53 status.
Cancer Gene Ther. 11:547-554(2004)

DOI=10.5282/edoc.3898
Euer N.I.
Identification of target genes for the therapy and diagnosis of ovarian carcinoma.
Thesis PhD (2005); Ludwig Maximilians University of Munich; Munich; Germany

PubMed=15706405; DOI=10.3892/or.13.3.375
Euer N.I., Kaul S., Deissler H., Mobus V.J., Zeillinger R., Weidle U.H.
Identification of L1CAM, Jagged2 and neuromedin U as ovarian cancer-associated antigens.
Oncol. Rep. 13:375-387(2005)